利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.042 秒)

    Methods for selectively modulating survivin apoptosis pathways
    3.
    发明授权
    Methods for selectively modulating survivin apoptosis pathways 有权
    选择性调节存活蛋白凋亡途径的方法

    公开(公告)号：US07553821B2

    公开(公告)日：2009-06-30

    申请号：US10291607

    申请日：2002-11-12

    申请人： Dario C. Altieri

    发明人： Dario C. Altieri

    IPC分类号： A61K48/00

    CPC分类号： G01N33/5011 ,  C07K16/18 ,  C12Q1/485 ,  G01N2500/00

    摘要： The present invention, based on the discovery of a new biological phenomena, provides methods and compositions for use in identifying agents that modulate the phosphorylation of survivin, the interaction between survivin and p34cdc2-cyclin B1 kinase complex, and the interaction between survivin and caspase-9. Related methods and compositions can be used to modulate survivin regulated apoptosis.

    摘要翻译： 本发明基于新生物现象的发现，提供了用于鉴定调节存活蛋白磷酸化的药物，存活蛋白和p34cdc2-细胞周期蛋白B1激酶复合物之间的相互作用以及存活蛋白和半胱天冬酶 - 9。 相关方法和组合物可用于调节存活蛋白调节的细胞凋亡。

    Methods for inhibiting endothelial cell and fibrinogen mediated inflammation using fibrinogen specific antibodies
    4.
    发明授权
    Methods for inhibiting endothelial cell and fibrinogen mediated inflammation using fibrinogen specific antibodies 失效
    使用纤维蛋白原特异性抗体抑制内皮细胞和纤维蛋白原介导的炎症的方法

    公开(公告)号：US06737058B2

    公开(公告)日：2004-05-18

    申请号：US09912741

    申请日：2001-07-24

    申请人： Dario C. Altieri ,  Lucia R. Languino ,  George B. Thornton

    发明人： Dario C. Altieri ,  Lucia R. Languino ,  George B. Thornton

    IPC分类号： A61K39395

    CPC分类号： C07K16/28 ,  A61K38/00 ,  C07K14/70525 ,  C07K14/75 ,  C07K16/2821 ,  C07K16/36 ,  C07K2317/34 ,  Y10S514/885

    摘要： The present invention contemplates therapeutic compositions containing a fibrinogen homolog capable of binding to endothelial cells in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Also described are therapeutic compositions containing an ICAM-1 homolog capable of binding to fibrinogen in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Methods of inhibiting endothelial cell and fibrinogen mediated inflammation within a patient by administering a homolog of this invention are also contemplated.

    摘要翻译： 本发明考虑了含有能够以不依赖RGD的方式结合内皮细胞的纤维蛋白原同源物的治疗组合物，其抑制纤维蛋白原与内皮细胞的结合。 还描述了含有能够以不依赖RGD的方式结合纤维蛋白原的ICAM-1同系物的治疗组合物，其抑制纤维蛋白原与内皮细胞的结合。 还考虑了通过施用本发明的同源物来抑制患者内皮细胞和纤维蛋白原介导的炎症的方法。

    Method for selectively modulating the interactions between survivin and tubulin
    5.
    发明授权
    Method for selectively modulating the interactions between survivin and tubulin 有权
    选择性调节存活蛋白与微管蛋白相互作用的方法

    公开(公告)号：US06346389B1

    公开(公告)日：2002-02-12

    申请号：US09283144

    申请日：1999-04-01

    申请人： Dario C. Altieri

    发明人： Dario C. Altieri

    IPC分类号： C12Q100

    CPC分类号： G01N33/6872 ,  G01N33/5011

    摘要： The present invention, based on the discovery of a new biological phenomena, provides methods and compositions for use in identifying agents which modulate the interaction between Survivin and polymerized tubulin or the mitotic spindles. Related methods and compositions can be used to modulate the interactions between Survivin and polymerized tubulin or the mitotic spindles, thereby modulating Survivin regulated apoptosis.

    摘要翻译： 本发明基于新生物现象的发现，提供了用于鉴定调节存活蛋白和聚合微管蛋白或有丝分裂轴之间的相互作用的试剂的方法和组合物。 相关方法和组合物可用于调节存活蛋白与聚合微管蛋白或有丝分裂丝心杆之间的相互作用，从而调节存活蛋白调节的细胞凋亡。

    Diagnostic methods useful in the characterization of lymphoproliferative disease characterized by increased EPR-1
    6.
    发明授权
    Diagnostic methods useful in the characterization of lymphoproliferative disease characterized by increased EPR-1 失效
    用于表征增加EPR-1的淋巴组织增生性疾病的诊断方法

    公开(公告)号：US06238875B1

    公开(公告)日：2001-05-29

    申请号：US08189309

    申请日：1994-01-28

    申请人： Dario C. Altieri

    发明人： Dario C. Altieri

    IPC分类号： G01N3353

    CPC分类号： C07K14/575 ,  A61K38/00 ,  A61K39/395 ,  C07K14/705 ,  C07K14/745 ,  C07K16/28 ,  C07K2317/74 ,  Y10S436/813

    摘要： A new class of cellular receptors extensively homologous but not identical to coagulation factors V and VIII is identified. These new cell surface receptors are designated effector cell protease receptors (EPRs) and include EPR-1, which is shown to bind protease ligands. The DNA and amino acid residue sequences of the receptor are also described. The invention also discloses methods, sequences and vectors useful in the purification and synthesis of cellular receptors of the present invention. Antibody compositions capable of immunoreacting with the receptor or with polypeptides containing the identified amino acid residue sequences and related therapeutic and diagnostic protocols are also described, as are polypeptides, compositions and methods relating to the inhibition of T lymphocyte proliferation using the antibodies disclosed herein. The receptors are also demonstrated to bind coagulation factor Xa, which binding is inhibited by various disclosed monoclonal antibodies to the receptors. The present invention also discloses polypeptides, antibodies and compositions capable of stimulating or co-stimulating lymphocyte proliferation.

    摘要翻译： 鉴定出与凝血因子V和VIII广泛同源但不完全相同的新一类细胞受体。 这些新的细胞表面受体被指定为效应细胞蛋白酶受体（EPR），并且包括EPR-1，其显示结合蛋白酶配体。 还描述了受体的DNA和氨基酸残基序列。 本发明还公开了可用于纯化和合成本发明的细胞受体的方法，序列和载体。还描述了能够与受体或含有鉴定的氨基酸残基序列和相关治疗和诊断方案的多肽免疫反应的抗体组合物 ，以及使用本文公开的抗体与T淋巴细胞增殖的抑制有关的多肽，组合物和方法。 还证明受体结合凝血因子Xa，其结合被各种公开的受体单克隆抗体抑制。 本发明还公开了能刺激或共刺激淋巴细胞增殖的多肽，抗体和组合物。